We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Anti-Müllerian Hormone Immunoassay Validated

By LabMedica International staff writers
Posted on 04 Nov 2019
Print article
Image: The MenoCheck picoAMH ELISA is FDA cleared for in vitro diagnostic use as an aid in the determination of menopausal status in women between 42 and 62 years of age (Photo courtesy of Ansh Laboratories).
Image: The MenoCheck picoAMH ELISA is FDA cleared for in vitro diagnostic use as an aid in the determination of menopausal status in women between 42 and 62 years of age (Photo courtesy of Ansh Laboratories).
Anti-Müllerian hormone (AMH) is a homodimeric glycoprotein with roles in regulation of fetal sexual differentiation and folliculogenesis in the adult ovary. AMH is increasingly used as a biomarker of ovarian reserve in clinical practice, and is used both for management of fertility treatments and prediction of menopause.

The most common method of measurement used for AMH is enzyme-linked immunosorbent assay (ELISA), although earlier ELISA assays have suffered from problems with sample stability and measurement variability. Newer-generation assays have equivalent performance with fewer reproducibility issues.

A team of scientists from Baylor College of Medicine (Houston, TX, USA) collected 28 serum samples were collected from patients for whom AMH testing was requested and were measured by two assays. A subset of the specimens used in accuracy studies was used to perform correlation of AMH measurements with antral follicle count (AFC). Reference ranges given by the manufacturer were verified using samples from 26 healthy female volunteers aged 22–41 years with samples tested as previously described.

The team sought to validate the newly FDA-approved MenoCheck picoAMH ELISA (Ansh Laboratories, Webster, TX, USA) on the Dynex-DS2 platform (Dynex Technologies, Chantilly, VA, USA) for clinical use in their obstetrics and gynecology center. Accuracy of the picoAMH ELISA on the Dynex-DS2 was determined by comparison with ELISA performed onsite at the Ansh Laboratories’ CLIA-certified laboratory.

The investigators reported that Intra- and inter-assay CV of the picoAMH assay on the DS2 was ≤4% and the assay was linear between concentrations of 0.0067–16.24 ng/mL (0.048–116.0 pmol/L) AMH. Method comparison was performed with the manufacturer’s laboratory and indicated good correlation. The assay displayed no significant interference from hemolysis (1,000 mg/dL), lipemia (2,000 mg/dL), conjugated bilirubin (66 mg/dL), or biotin (10,000 ng/mL). Measurement of AMH on the DS2 was also correlated with antral follicle count, with R = 0.7128.

The authors concluded that their results indicate that the picoAMH ELISA on the DS2 has good analytical performance suitable for clinical use and that it can be used for patient testing in the reproductive endocrinology and infertility/in vitro fertilization (REI/IVF) setting in their hospital. The study was published in the November 2019 issue of the journal Practical Laboratory Medicine.

Related Links:
Baylor College of Medicine
Ansh Laboratories
Dynex Technologies


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A blood test could predict lung cancer risk more accurately and reduce the number of required scans (Photo courtesy of 123RF)

Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans

Lung cancer is extremely hard to detect early due to the limitations of current screening technologies, which are costly, sometimes inaccurate, and less commonly endorsed by healthcare professionals compared... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Pathology

view channel
Image: Comparison of traditional histopathology imaging vs. PARS raw data (Photo courtesy of University of Waterloo)

AI-Powered Digital Imaging System to Revolutionize Cancer Diagnosis

The process of biopsy is important for confirming the presence of cancer. In the conventional histopathology technique, tissue is excised, sliced, stained, mounted on slides, and examined under a microscope... Read more